XOMA Royalty Corporation (XOMA)
NASDAQ:XOMA
Want to see XOMA full AI Analyst Report?
XOMA Stock Chart & Stats
$39.71
$0.08(0.31%)
At close: 4:00 PM EST
$39.71
$0.08(0.31%)
Day’s Range― - ―
52-Week Range$22.29 - $42.81
Previous CloseN/A
Volume8.24K
Average Volume (3M)53.64K
Market Cap
$744.28M
Enterprise Value$553.36M
Total Cash (Recent Filing)$94.96M
Total Debt (Recent Filing)$124.73M
Price to Earnings (P/E)15.9
Beta1.42
Next Earnings
Jul 30, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.65
Shares Outstanding17,553,810
10 Day Avg. Volume49,949
30 Day Avg. Volume53,642
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)4.60
Price to Sales (P/S)9.17
P/FCF Ratio166.54
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue15.27
Enterprise Value/Gross Profit16.37
Enterprise Value/Ebitda11.03
Forecast
1Y Price Target
$39.00Price Target Upside-1.79% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.79
Revenue Forecast (FY)$60.73M
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationXOMA’s operating and free cash flow turning positive in 2025 and strengthening in the trailing twelve months is a durable improvement. Positive cash generation supports organic reinvestment, bolt-on royalty acquisitions, share repurchases and debt servicing, increasing strategic optionality versus prior negative-cash years.
Profitability TurnaroundA return to strong net income and consistently high gross margins in 2025 and TTM indicate improved earnings power. Sustained profitability supports reinvestment into the royalty portfolio, funds milestone-backed deals, and provides a buffer against future volatility in single-asset payments.
Diversifying Royalty PortfolioActive portfolio expansion—multiple asset additions, acquisitions and a widened Takeda collaboration—strengthens durable cash diversity. A broader mix of commercial and mid-stage royalties reduces single-product concentration risk and increases the probability of steady future cash receipts and milestone upside.
Bears Say
LeverageLeverage with debt exceeding equity materially constrains financial flexibility. Higher debt amplifies downside in revenue stress, increases interest costs, and limits the company’s ability to pursue opportunistic acquisitions or withstand prolonged royalty shortfalls without dilutive financing or asset sales.
Revenue/Profit VolatilityRecent swings—solid 2025 results followed by a TTM revenue decline—illustrate unstable royalty cash flows driven by product timing and milestones. This volatility complicates forecasting, raises working-capital needs at times, and weakens the predictability of long-term free cash flow for reinvestment or debt reduction.
Transaction & Litigation RiskThe pending Ligand acquisition and a contingent value right tied to litigation create structural execution risk. Closing, regulatory approvals, integration and litigation outcomes can materially change timing and quantum of returns to shareholders and may alter strategy, capital allocation and portfolio continuity post-close.
XOMA Royalty Corporation News
XOMA FAQ
What was XOMA Royalty Corporation’s price range in the past 12 months?
XOMA Royalty Corporation lowest stock price was $22.29 and its highest was $42.81 in the past 12 months.
What is XOMA Royalty Corporation’s market cap?
XOMA Royalty Corporation’s market cap is $744.28M.
When is XOMA Royalty Corporation’s upcoming earnings report date?
XOMA Royalty Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 53 days.
How were XOMA Royalty Corporation’s earnings last quarter?
XOMA Royalty Corporation released its earnings results on Apr 30, 2026. The company reported $0.168 earnings per share for the quarter, beating the consensus estimate of $0.128 by $0.04.
Is XOMA Royalty Corporation overvalued?
According to Wall Street analysts XOMA Royalty Corporation’s price is currently Overvalued.
Does XOMA Royalty Corporation pay dividends?
XOMA Royalty Corporation does not currently pay dividends.
What is XOMA Royalty Corporation’s EPS estimate?
XOMA Royalty Corporation’s EPS estimate is 0.18.
How many shares outstanding does XOMA Royalty Corporation have?
XOMA Royalty Corporation has 17,553,810 shares outstanding.
What happened to XOMA Royalty Corporation’s price movement after its last earnings report?
XOMA Royalty Corporation reported an EPS of $0.168 in its last earnings report, beating expectations of $0.128. Following the earnings report the stock price went down -0.122%.
Which hedge fund is a major shareholder of XOMA Royalty Corporation?
Currently, no hedge funds are holding shares in XOMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
XOMA Royalty Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$39.00 (-1.79% Downside)
$39.00 (-1.79% Downside)
Hedge Fund Trend
Increased
By 377.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.28%
12-Months-Change
Fundamentals
Return on Equity
30.21%
Trailing 12-Months
Asset Growth
27.78%
Trailing 12-Months
Company Description
XOMA Royalty Corporation
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Company Deck
XOMA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial story: substantial year-over-year revenue and royalty growth, a large and diversified expansion of the royalty portfolio, positive GAAP net income and operating cash flow, meaningful liquidity ($≈83M), and shareholder returns via buybacks. Offsetting risks include recent Phase III clinical setbacks, ongoing litigation with uncertain outcomes and associated costs, some reliance on non-cash GAAP gains, and interest and cash outflows that reduced unrestricted cash modestly. Overall, the company portrays momentum toward an inflection point where royalties may cover operating costs, but execution risks from development-stage assets and litigation remain.View all XOMA earnings summariesXOMA Stock 12 Month Forecast
Average Price Target
$39.00
▼(-1.79% Downside)
Technical Analysis
Ocugen
―
Corvus Pharmaceuticals
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.76% Insiders
13.55% Mutual Funds
24.47% Other Institutional Investors
44.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---